

INSTITUTO DE LA QUÍMICA Y METABOLISMO DEL FÁRMACO

CONICET



IQUIMEFA



CONSEJO NACIONAL DE INVESTIGACIONES CIENTÍFICAS Y TÉCNICAS
FACULTAD DE FARMACIA Y BIOQUÍMICA – UNIVERSIDAD DE BUENOS AIRES

DRUG DISCOVERY FOR NEGLECTED DISEASES INTERNATIONAL CONGRESS 2018

**4th Scientific Meeting of the Research Network
Natural Products against Neglected Diseases**



DDNDIC 2018



Book of abstracts

4th – 6th December 2018

Facultad de Farmacia y Bioquímica – Universidad de Buenos Aires
Ciudad Autónoma de Buenos Aires, Argentina

Drug Discovery for Neglected Diseases International Congress 2018
4th Scientific Meeting of the Research Network Natural Products against Neglected Diseases
4th – 6th December 2018
Facultad de Farmacia y Bioquímica - Universidad de Buenos Aires
Ciudad Autónoma de Buenos Aires, Argentina

*This event has been declared of interest by the Cámara de Diputados and the Cámara de Senadores de la Nación and
has been additionally declared of sanitary interest by
the Legislatura de la Ciudad Autónoma de Buenos Aires*

Book of abstracts

ISBN: 978-987-47034-0-8
General coordination: Albertina Gladys Moglioni
Edited by Valeria Patricia Sülsen and Flavia del Carmen Redko

Drug Discovery for Neglected Diseases International Congress 2018: book of
abstracts;
coordinación general de Albertina Gladys Moglioni ; editado por Valeria Patricia
Sülsen; Flavia del Carmen Redko. - 1a ed. - Ciudad Autónoma de Buenos Aires:
IQUIMEFA, 2018.
Libro digital, PDF

Archivo Digital: descarga y online
ISBN 978-987-47034-0-8

I. Lucha Contra las Enfermedades. I. Moglioni, Albertina Gladys, coord. II. Sülsen,
Valeria Patricia, ed. III. Redko, Flavia del Carmen, ed.

CDD 540

Address of correspondence

Dr Albertina Moglioni
Dr. Valeria P. Sülsen
Instituto de la Química y Metabolismo del Fármaco (IQUIMEFA) (UBA- CONICET),
Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires
Junín 956, 1113, Buenos Aires, República Argentina
Phone +54 11 5287-4272 Fax +54 11 4508-3642
iquimefa@ffyb.uba.ar
amoglio@ffyb.uba.ar
vsulsen@ffyb.uba.ar



DDNDIC 2018

Drug Discovery for Neglected Diseases International Congress 2018
4th Scientific Meeting of ResNet NPND

Buenos Aires, Argentina
4th – 6th December 2018



Charge density as a molecular descriptor to reveal differences on high active cruzain inhibitors

Luchi A. M.¹, Bogado M.¹, Villafañe R. N.¹, Angelina L. E.¹, Peruchena N. M.¹

Lab. Estructura Molecular y Propiedades, IQUIBA-NEA, Universidad Nacional del Nordeste, CONICET,
FACENA, Av.Libertad 5470, Corrientes 3400, Argentina.
adrianoluchi93@gmail.com

Available chemotherapy for Chagas disease (CD) involves severe side effects and drug- resistance has been observed in some trypanosome strains. Thus, the discovery of new, safer and more effective drugs to treat CD is required ^[1]. Cruzain (Cz), a cysteine protease of the papain-like family, plays a vital role at every stage of the parasite's life cycle. The active-site region of enzyme is similar to those of other members of the papain superfamily with seven substrate-binding subsites, four (S4, S3, S2, S1) on the acyl side and three (S1', S2', S3') on the amino side of the cleaved substrate bond ^[2].

Currently, 25 inputs associated to this molecular target are registered in the Protein Data Bank (rcsb.org), where Cz has been co-crystallized with reversible and irreversible inhibitors. Thereby, Cz presents itself as an interesting target for development of potential therapeutics for the treatment of the disease by employing a structure-based approach. Among Cz inhibitors, those containing a vinyl sulfone warhead can exhibit good selectivity and a favorable in vivo safety profile despite the irreversible nature of inhibition ^[1].

Jaishankar et al. synthesized and determined the inhibition constant (and binding energies, ΔG) of a series of vinyl sulfone analogs. However, the analysis of key interactions among sub-pockets, that might explain the activity differences between the ligands, is not available yet ^[3].

The quantum theory of atoms in molecules (QTAIM) provides an important insight into the molecular interactions in ligand-receptor (L-R) complexes ^[4]. Through the mapping of the gradient vector field onto the complex charge density, a series of topological elements arise. Among these topological elements, the bond critical point (BCP) and, in particular, the charge density value (ρ_b) at an interaction BCP is considered as a measure of that interaction strength.

Unlike ΔG that is a global property of the entire system, ρ_b is a local property measured at each interaction BCP. This means that ρ_b can be used to decompose the binding energy in contributions by groups of atoms ^[5].

Accordingly, the aim of this work was to exploit charge density to decompose total binding energy in contributions by sub-pockets of Cz. In other words, we want to know how strong is the anchoring of known inhibitors to each Cz sub-pocket. This analysis allowed us to identify easily the anchoring points that could be improved (by optimizing inhibitors structure) in order to increase inhibitor affinity to Cz.



DDNDIC 2018

Drug Discovery for Neglected Diseases International Congress
2018

4th Scientific Meeting of ResNet NPND
Buenos Aires, Argentina
4th - 6th December 2018



CHARGE DENSITY AS A MOLECULAR DESCRIPTOR TO REVEAL DIFFERENCES ON HIGH ACTIVE CRUZAIN INHIBITORS

Luchi, A. M.¹, Bogado, M.¹, Villafañe, R. N.¹, Angelina, L. E.¹, Peruchena, N. M.¹

Lab. Estructura Molecular y Propiedades, IQUIBA-NEA, Universidad Nacional del Nordeste, CONICET,
FACENA, Av.Libertad 5470, Corrientes 3400, Argentina
adrianoluchi93@gmail.com

Abstract

Available chemotherapy for Chagas disease (CD) involves severe side effects and drug-resistance has been observed in some trypanosome strains. Thus, the discovery of new, safer and more effective drugs to treat CD is required (1).

Cruzain (Cz), a cysteine protease of the papain-like family, plays a vital role at every stage of the parasite's life cycle. The active-site region of enzyme is similar to those of other members of the papain superfamily with seven substrate-binding subsites, four (S4, S3, S2, S1) on the acyl side and three (S1', S2', S3') on the amino side of the cleaved substrate bond (2).

Currently, 25 inputs associated to this molecular target are registered in the Protein Data Bank (rcsb.org), where Cz has been co-crystallized with reversible and irreversible inhibitors. Thereby, Cz presents itself as an interesting target for development of potential therapeutics for the treatment of the disease by employing a structure-based approach.

Among Cz inhibitors, those containing a vinyl sulfone warhead can exhibit good selectivity and a favorable in vivo safety profile despite the irreversible nature of inhibition (1).

Jaishankar et al. synthesized and determined the inhibition constant (and binding energies, ΔG) of a series of vinyl sulfone analogs. However, the analysis of key interactions among sub-pockets, that might explain the activity differences between the ligands, is not available yet (3).

The quantum theory of atoms in molecules (QTAIM) provides an important insight into the molecular interactions in ligand-receptor (L-R) complexes (4). Through the mapping of the gradient vector field onto the complex charge density, a series of topological elements arise. Among these topological elements, the bond critical point (BCP) and, in particular, the charge density value (ρ_b) at an interaction BCP is considered as a measure of that interaction strength.

Unlike ΔG that is a global property of the entire system, ρ_b is a local property measured at each interaction BCP. This means that ρ_b can be used to decompose the binding energy in contributions by groups of atoms (5).

Accordingly, the aim of this work was to exploit charge density to decompose total binding energy in contributions by sub-pockets of Cz. In other words, we want to know how strong is the anchoring of known inhibitors to each Cz sub-pocket. This analysis allowed us to identify easily the anchoring points that could be improved (by optimizing inhibitors structure) in order to increase inhibitor affinity to Cz.



DDNDIC 2018

Drug Discovery for Neglected Diseases International Congress
2018

4th Scientific Meeting of ResNet NPND
Buenos Aires, Argentina
4th - 6th December 2018





Figure1. A) Interactions of Cz inhibitor at the binding pocket. **B)** Charge density values at the BCPs in Cz-inhibitor complexes. Inhibitors naming taken from Ref 3. Sub-pockets S1 (blue stacked bars), S1' (green stacked bars), S2 (orange stacked bars) and S3 (red stacked bars).

INSTITUTO DE LA QUÍMICA Y METABOLISMO DEL FÁRMACO



IQUIMEFA



CONSEJO NACIONAL DE INVESTIGACIONES CIENTÍFICAS Y TÉCNICAS
FACULTAD DE FARMACIA Y BIOQUÍMICA – UNIVERSIDAD DE BUENOS AIRES



Drug Discovery for Neglected Diseases International Congress
2018

4th Scientific Meeting of ResNet NPND

Buenos Aires, Argentina
4th - 6th December 2018



Keywords. QTAIM, Molecular Dynamics, K-777

References.

- 1) Wiggers, H. J., Rocha, J. R., Fernandes, W. B., Sesti-Costa, R., Carneiro, Z. A., Cheleski, J., ... Montanari, C. A. (2013). Non-peptidic Cruzain Inhibitors with Trypanocidal Activity Discovered by Virtual Screening and In Vitro Assay. *PLoS Neglected Tropical Diseases*, 7(8).
- 2) Brinen, L. S., Hansell, E., Cheng, J., Roush, W. R., McKerrow, J. H., & Fletterick, R. J. (2000). A target within the target: Probing cruzain's P1' site to define structural determinants for the Chagas' disease protease. *Structure*, 8(8), 831–840.
- 3) P. Jaishankar, E. Hansell, D. M. Zhao, P. S. Doyle, J. H. McKerrow, A. R. Renslo, *Bioorganic & Medicinal Chemistry Letters*, 2008, 18, 624–628.
- 4) R. W. Bader, *Atoms in Molecules: A Quantum Theory*, Oxford University Press, New York, 1990.
- 5) E. Angelina, S. Andujar, R.D. Tosso, R.D. Enriz, N. Peruchena, Non-covalent interactions in receptor-ligand complexes. A study based on the electron charge density, *J. Phys. Org. Chem.* 27 (2014) 128e134.